Lumendi LLC
$164.6K 83 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Resmed Corp
Resmed Corp reported $164,642.38 across General Payments, Research, and Ownership to 1,167 physicians and teaching hospitals across 1,169 transactions.
- $164.6K
- All-tracks total
- 1,169
- Transactions
- 1,167
- Recipients
- −$63.2K
- General Payments vs PY2023
Resmed Corp reported $164,642.38 across all CMS Open Payments tracks (General + Research + Ownership) to 1,167 physicians and teaching hospitals in Program Year 2024 - ranking #1058 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $160,396.77, averaging $141.08 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer resmed-corp Resmed Corp
$164.6K · #1058/1,925 · 0.0% industry · PY2024
- TOT $164.6K
- RANK #1058
- SHARE 0.0%
- TXN 1,169
- RCP 1,167
- CAT 4
- GEN $160.4K
- ΔGEN −$63.2K
- TOP1 25.8%
- PY 2024
Volume peers
Nearest volume peer: Lumendi LLC ($164.6K)
Resmed Corp sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Resmed Corp's CMS-reported General Payments decreased by $63.2K (−28.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: RESMED CORPPY2023: RESMED CORPPY2024: Resmed Corp. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $223,555.43
- PY2024
- $160,396.77
What the Data Shows for Resmed Corp
In Program Year 2024, Resmed Corp reported $164,642.38 in payments to 1,167 physicians and teaching hospitals across 1,169 individual transactions, an average of $140.84 per transaction and $141.08 per recipient. That total places Resmed Corp at rank #1058 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
Of the 4 general-payment categories charted below, "Consulting Fee" is the largest at $115.9K across 20 transactions, 72.2% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Resmed Corp's 4-category general-payment breakdown at $115.9K, 72.2% of the reported total.
Resmed Corp reports 4 general-payment categories - the top three are Consulting Fee (72.2%), Food and Beverage (14.6%), and Royalty or License (10.6%). The remaining 1 category make up 2.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Resmed Corp divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $115.9K | 20 | 72.2% |
| Food and Beverage | $23.3K | 1,053 | 14.6% |
| Royalty or License | $17.0K | 3 | 10.6% |
| Education | $4.2K | 91 | 2.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $119,616.50 (74.6%) of $160,396.77 in this company's General Payments records across 946 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Resmed Corp
The five named recipients with the highest reported General Payments from this company
- 1
Ucsd Medical Center
$41,390.00 across 2 reported transactions
- 2
Emerson Wickwire
$25,000.00 across 4 reported transactions
- 3
Board Of Trustees Of The University
$20,400.00 across 2 reported transactions
- 4
University Of Washington Med Ctr
$20,326.50 across 5 reported transactions
- 5
Namratha Reddy
$12,500.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Resmed Corp's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Resmed Corp.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Resmed Corp.
Showing 6 of 1,924 companies with CMS-reported payment data.
BK Medical Holding Company Inc.
$164.8K 84 recipients
Compare payment profiles
Gotham Surgical Solutions & Devices, Inc.
$164.9K 245 recipients
Compare payment profiles
SweetBio, Inc.
$165.0K 1 recipients
Compare payment profiles
Avertix Medical, Inc
$164.0K 25 recipients
Compare payment profiles
B. Braun Melsungen AG
$165.4K 5 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.